Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$102.69 USD

102.69
437,265

-0.38 (-0.37%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $102.72 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (93 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing

by Zacks Equity Research

The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.

Zacks Equity Research

QIAGEN's New Offerings to Broaden Hematology Testing Suite

by Zacks Equity Research

QIAGEN (QGEN) continues to progress with test menu expansion.

Zacks Equity Research

Here's Why You Should Invest in Surmodics (SRDX) Right Now

by Zacks Equity Research

A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.

Zacks Equity Research

BD Brings HealthSight Diversion App to Combat Opioid Crisis

by Zacks Equity Research

BD's (BDX) latest development is likely to boost the company's Medication Management unit.

Zacks Equity Research

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

by Zacks Equity Research

Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.

Zacks Equity Research

Varian Medical's (VAR) Halcyon Gets NMPA Approval in China

by Zacks Equity Research

Varian Medical (VAR) enjoys significant international presence in radiotherapy.

Zacks Equity Research

Walgreens Gains from New Alliances, International Expansion

by Zacks Equity Research

Walgreens Boots (WBA) is benefiting from strategic tie-ups. The Express Scripts and Kroger deals are intended to expand its existing group purchasing efforts and product offerings.

Zacks Equity Research

Integra's (IART) Margin Pressure Hurts, Global Prospects High

by Zacks Equity Research

Massive gross margin declines induced by mounting costs are a major downside for Integra LifeSciences (IART).

Zacks Equity Research

PRA Health Launches PSN to Expand in Pediatric Care, Stock Up

by Zacks Equity Research

PRA Health's (PRAH) Center for Pediatric Clinical Development is likely to enhance pediatric clinical testing and design with the latest move.

Zacks Equity Research

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

by Zacks Equity Research

Thermo Fisher (TMO) gains on strength in all end markets. It witnesses consistent growth in the Asia-Pacific and emerging markets.

Zacks Equity Research

Quest Diagnostics to Buy Laboratory Services Unit in Midwest

by Zacks Equity Research

Quest Diagnostics (DGX) continues to expand inorganically. The latest buyout is expected to expand the company's portfolio in the Midwest.

Zacks Equity Research

CVS Health (CVS) Gets Final Approval to Close Aetna Deal

by Zacks Equity Research

Both CVS Health (CVS) and Aetna are hopeful about this consolidation, which is aimed at revolutionizing consumer health care experience and substantial cost reduction.

Zacks Equity Research

Medtronic (MDT) Positive on Mazor Purchase, Rising Costs Ail

by Zacks Equity Research

The pending acquisition of Mazor Robotics holds great potential as it is likely to solidify Medtronic's (MDT) position in robotic spine surgery.

Zacks Equity Research

Align Technology's New iTero Scanner Updates to Boost Uptake

by Zacks Equity Research

Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

Zacks Equity Research

Edwards Lifesciences' Critical Care Arm Solid, THVT View Dull

by Zacks Equity Research

Edwards Lifesciences (EW) sees strong Critical Care division sales. Management expects sluggish underlying THVT sales for 2018.

Zacks Equity Research

Here's Why You Should Invest in Merit Medical (MMSI) Now

by Zacks Equity Research

A strong outlook for 2018 and a solid global foothold make Merit Medical (MMSI) a promising investment pick.

Zacks Equity Research

Here's Why You Should Invest in Abiomed (ABMD) Right Now

by Zacks Equity Research

Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.

Zacks Equity Research

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

by Zacks Equity Research

Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.

Zacks Equity Research

Here's Why You Should Buy Intuitive Surgical (ISRG) Now

by Zacks Equity Research

Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.

Zacks Equity Research

Here's Why You Should Buy Integer Holdings (ITGR) Stock Now

by Zacks Equity Research

Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.

Zacks Equity Research

Zacks.com featured highlights include: K12, Great Lakes Dredge, Luxfer, Integer Holdings and STAAR

by Zacks Equity Research

Zacks.com featured highlights include: K12, Great Lakes Dredge, Luxfer, Integer Holdings and STAAR

Zacks Equity Research

5 Stocks With Recent Price Strength to Maximize Your Gains

by Zacks Equity Research

Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

Zacks Equity Research

Integer Holdings (ITGR) Beats on Q3 Earnings and Revenues

by Zacks Equity Research

Integer Holdings (ITGR) gains from solid Medical sales contribution in Q3; 2018 guidance solid.

Zacks Equity Research

Integer (ITGR) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 15.22% and 4.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What's in Store for Integer Holdings (ITGR) in Q3 Earnings?

by Zacks Equity Research

The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.